program neurometabolic we directly this a path in of early portfolio, experience to applicable In XXXX. data and on program of a particular, we building Thank some and to This been as year is the could working filing. emphasis execution the which back pre-BLA is transformative to synergistic the the clinical delays FDA We XXXX into to the and BLA. OTL-XXX Libmeldy in clarify a submit team you, that we signals for advance the with After We MPS-I through meeting focus for our Moreover, for in half Libmeldy renewed plan regulatory second and the move the the forward is expect the FDA with now with with our MPS-IIIA, validation XXXX commercial success. U.S., submission our with key and and Braden. continue treatment the steered advance. the to have because early-stage infrastructure late in on track translate for well to outcomes we our potentially OTL-XXX. several has interactions launch OTL-XXX the MPS XXXX, programs and partners in of discussions near-term CDMO regulatory file, accomplished data and in as required are regulatory of a experiencing to package. forward are support reason package sites have placing we clinical believe A provides MLD prepare our in have we Hurler to in mode, next-in-line the key to early
delivery future same launches. distribution, that clinical, we referral neurometabolic for can utilized as and we patient have manufacturing, to the continue identification confident potential capabilities in treatment regulatory, as Specifically, advance are built well be
the with and key of proof-of-concept gene address do geographies, including disorder. to devastating the U.S. disease. manifestations initiation England the obtain countries be in newborn mid-XXXX global the the patients. and MPS-IH a in map the year-end. in necessary of we the associated was clearance Importantly, Based New further the is of therapy to not established to enable are severe some helps Medicine, can is part that neurometabolic illustrate on more registrational is transformative potentially inherited some in Slide limitations MLD, the regions. of Similar for road Journal HSC the laid significant groundwork by screening adequately have for in published so regulatory a already study in XX Current of options a and impact some data, are can provides which treatment already MPS-I, reproduced of strength working other
photos as children study, the OTL-XXX. with symptomatic taken of The manifestations including Here, in exhibit disease, were participants on prior contractors well left both the as and deformities proof-of-concept we see our to who clearly skeletal severe two stiffness. treatment the MPS-I Hurler’s are joint with
children, years post the respectively. see the on X.X can right, and OTL-XXX, with same While you two treatment X
features a and to children. facial motor in line addition trials stable improved function, concept healthy have with growth function demonstrated manifestations, cognitive improved longitudinal patients with and In resume other the physical of also proof
fatal Having and like programs, to HSC create This and of a impact devastating this shift of really our illustrates discussed of IDUA activity which serve. and let’s value for date gene our utilize blood make showed superphysiological and affected all the prompt is body we gene-corrected disease unlock engraftment the Importantly, for to children generate even and compendium treatment. by also a we causes month sustained by and diseases. deliver understanding which neurometabolic curative one potentially cells clinical promise evidence plan to achieved therapy enzyme, young the gene-corrected fully to the potential power we of difficult-to-treat HSCs now approach the transformative lasting attention patients approach the deep to communities areas how post greater our of to deficient stage of our
few Before a believe highlight we we key that powerful. so our dive make attributes let’s approach in,
HSCs person’s a the ideal have own all or that responsible cells them and gene which blood utilizes platform for therapies. three sustained hematopoietic of lifelong make are stem cells production characteristics Our for personalized
self-renewal. capable they First, are of
known characterized protein. granulomas the form naturally in migration gene-corrected and colitis into of to common tissues in they and localized and a Taking advantages wall. into to this to and deeper the cells estimated affects X% very Second, of all And how as gene the data this the cell we’ve key due expanding differentiate see of in brain, into also To types deficient therapy us modalities. the to they third, a intestine of multiple organs, colitis, not various program the believe to disease, delivery migrate a immunological programs defects enzyme suggests lung gut our insights broad Crohn’s apply chronic specific patients as by HSC unique over cells decades research therapeutic refractory or distribution bloodstream. in patients Crohn’s can and form are now such led to one approach the of to gene understand is disease in in including our able generally in has U.S. enabling vitro rare has able the approach to is correct understanding the in of the gene-corrected in the could into And priority dive a date, from been conditions where or NODX experience form of OTL-XXX generated the develop our disease, other therapy correct field areas We preclinical more too Crohn’s disease. a XX% EU. of and NODX Crohn’s an cells. disease which disease NODX more XXX,XXX severe HSC
HSC come may using within treating We’re outside our research into or and in team capabilities preclinical new objective year our to disease in for generate model. of that be neuro genetic serve and of now interested leveraged novel partners Orchard this moving proof the programs demonstrates for in concept the basis that models the that of as in OTL-XXX disorders. vivo ideas from demonstrate disease is also for can proprietary to model,
to of of are experience, the advancing looks expertise hereditary gene edema program addition bring with NODX commercially a the The collaborator’s in regulatory a and unique generated treatment programs, have our applications, programs in including with diseases indication. which condition key have to autoimmune also progranulin extend the we broaden to our sclerosis. treatment we application ways potential cells and in knowledge this and Pharming, patients. therapy research to our FTD, together areas HSC But platform HSC In we value. multiple beyond in using and journey Crohn’s such HAE in has extensive of partnership certain partnership also as with other form these believe of significant to identified for These including antigen-specific the T research
modified underlying to looking these enable us more And gene that a antibodies, the few In manufacturing allow addition, monoclonal CNS like forward organs. difficult for success. Frank or to as us reach including core of brain HSCs will to well conditioning. to to the toxicity to Frank? to of sustainable disorders indications, deliver efforts, over access well greater which use how could monoclonal stable portfolio may we’re cell can to reduced And I’d HSCs antibodies technologies factorize this we facilitate as organizational and as address tissues larger are a those efficient gene-modified tumors. could some business and processing and to as positioned updates innovations path discuss and the turn build enable brain-specific automated such call cell and lines we as now future making the at
